IP Library Granted Patent US 10,001,471
Granted Patent B2
US 10,001,471 · App. 14/448,436 · Granted Jun 19, 2018

In vitro test system to evaluate xenobiotics as immune-modulators of drug transport and metabolism in human hepatocytes

Inventors: Maciej Czerwinski (Fairway, KS); David Benjamin Buckley (Olathe, KS); Faraz Kazmi (Overland Park, KS)
Assignee: XENOTECH LLC
G01N33/5067G01N33/5014G01N33/5023G01N2500/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,001,471
App. No.
14/448,436
Granted
Jun 19, 2018
Kind
B2
Abstract

A kit and method for evaluating in vitro the effect of a xenobiotic (e.g., a biologic drug) on drug metabolism in hepatocytes. The kit comprises a first culture of hepatocytes, a portion of in vitro xenobiotic-stimulated biological sample, and instructions for incubating the first culture of hepatocytes with the portion of in vitro xenobiotic-stimulated biological sample, and analyzing the activity, expression, or a combination thereof of a biomarker in the hepatocytes to evaluate the effect of the xenobiotic on drug metabolism in the hepatocytes.

Claims (15)

1. A kit for evaluating in vitro the effect of a xenobiotic on drug metabolism in hepatocytes, said kit comprising:

cryopreserved hepatocytes;

an in vitro xenobiotic-stimulated biological sample, wherein said biological sample has been stimulated in vitro by said xenobiotic for about 12 to about 48 hours to yield said in vitro xenobiotic-stimulated biological sample, wherein said biological sample is selected from the group consisting of whole blood, bone marrow, and isolated peripheral blood mononuclear cells, wherein said xenobiotic is a small molecule or biologic drug; and

instructions for incubating said hepatocytes with said in vitro xenobiotic-stimulated biological sample and analyzing the activity, expression, or a combination thereof of a biomarker in said hepatocytes to evaluate the effect of said xenobiotic on drug metabolism in said hepatocytes.

2. The kit of claim 1 , wherein said cryopreserved hepatocytes further comprise Kupffer cells.

3. The kit of claim 1 , wherein said hepatocytes are human hepatocytes.

4. The kit of claim 1 , wherein said hepatocytes are pooled hepatocytes.

5. The kit of claim 4 , wherein said pooled hepatocytes comprise a combination of cells from different genders, genotypes, ages, races, enzymatic or metabolic activities, species, or disease or health states.

6. The kit of claim 1 , wherein said in vitro xenobiotic-stimulated biological sample is a portion of in vitro xenobiotic-stimulated biological sample prepared by exposing a first culture of said biological sample to said xenobiotic in vitro to yield a xenobiotic-stimulated biological sample, and separating said portion of said xenobiotic-stimulated biological sample.

7. The kit of claim 6 , wherein said portion of in vitro xenobiotic-stimulated biological sample is plasma that has been separated from said in vitro xenobiotic-stimulated whole blood.

8. The kit of claim 6 , wherein said portion of in vitro xenobiotic-stimulated biological sample is a cytokine-containing fraction that has been separated from said in vitro xenobiotic-stimulated bone marrow.

9. The kit of claim 6 , wherein said portion of in vitro xenobiotic-stimulated biological sample is a cytokine-containing fraction that has been separated from said in vitro xenobiotic-stimulated peripheral blood mononuclear cells.

10. The kit of claim 1 , wherein said xenobiotic is a biologic drug.

11. The kit of claim 10 , wherein said biologic drug is selected from the group consisting of hormones, growth factors, cytokines, receptors, antibodies, enzymes, oligonucleotides, aptamers, synthetic peptides, and vaccines.

12. The kit of claim 1 , wherein said in vitro xenobiotic-stimulated biological sample further comprises an anticoagulant.

Assignments (2)
SECURITY INTEREST Recorded Sep 8, 2023
From: XENOTECH, L.L.C.
To: ARES CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
Reel/Frame 064850/0265 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 31, 2014
From: CZERWINSKI, MACIEJ; BUCKLEY, DAVID BENJAMIN; KAZMI, FARAZ
To: XENOTECH LLC
Reel/Frame 033437/0341 →
Continuity (3)
Division 13481295 · May 25, 2012
Provisional Application 61490931 · May 27, 2011
Related Publication 20140342944A1 · Nov 20, 2014